FIA
PMCB icon

FNY Investment Advisers’s PharmaCyte Biotech PMCB Stock Holding History

FNY Investment Advisers’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31,100
Closed -$90K – 687
2022
Q4 		$90K Buy
+31,100
New +$89.1K 0.13% 145
2022
Q3 		– Sell
-15,290
Closed -$34K – 792
2022
Q2 		$34K Sell
15,290
-43,776
-74% -$95.7K 0.03% 269
2022
Q1 		$135K Buy
+59,066
New +$131K 0.13% 147

Other funds holding PMCB

AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FNY Investment Advisers's PMCB Position: Q1 2023 in Review

FNY Investment Advisers sold out of PharmaCyte Biotech (PMCB) in Q1 2023, closing a stake of 31,100 shares — an estimated $90K sold.

FNY Investment Advisers first reported a position in PMCB in Q1 2022 and held it in 3 quarters. The position peaked at $135K in Q1 2022. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2023.

  • FNY Investment Advisers reported no remaining PharmaCyte Biotech position as of Q1 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 31,100 PharmaCyte Biotech shares in Q1 2023, an estimated $90K.
  • FNY Investment Advisers first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 3 quarters.
  • FNY Investment Advisers's PharmaCyte Biotech position peaked at $135K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2023.

Based on FNY Investment Advisers's 13F filing for Q1 2023, filed 12 Apr 2023.